OXiGENE (NASDAQ:OXGN) appoints Bill Schwieterman, M.D., as President and CEO replacing current CEO Dai Chaplin, Ph.D., who will become Chief Scientific Officer. Previously, Dr. Schwieterman was Chief Medical Officer at Chelsea Therapeutics.
Diversification is a symptom of weakness.
no decision, without knowledge and confidence in
oneself, NOTHING.
**make their own decisions, not those of anyone.